Oligonucleotide-based therapeutics represent a new class of medicines with the potential to treat a wide range of diseases. By interfering with how genes are expressed, these short nucleic acid polymers can enable more precision and a more personalised medicine approach, as they can theoretically target any gene with minimal, or predictable, off-target effects (1).   … Continue reading Transforming oligonucleotide manufacturing